Company
LEO Pharma
LEO Pharma has 53 drugs tracked on RxWires: 6 post-market, 5 approved, 12 in Phase 3, 9 in Phase 2, 2 in Phase 1/2, 16 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Enstilar Foam | Post-Market | Nail Psoriasis |
| clobetasol | Post-Market | Dermatitis, Contact |
| Tinzaparin | Post-Market | Kidney Failure, Chronic |
| Fucidin® cream | Post-Market | Impetigo |
| Enstilar 0.005%-0.064% Topical Foam | Post-Market | Psoriasis |
| Spesolimab | Post-Market | Generalized Pustular Psoriasis |
| CEVIMELINE HYDROCHLORIDE | Approved | |
| PICATO | Approved | |
| DESVENLAFAXINE SUCCINATE | Approved | |
| OLANZAPINE | Approved | |
| LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Approved | |
| Prophylactic anticoagulation ( INNOHEP®) | Phase 3 | Anemia |
| Calcipotriol plus betamethasone dipropionate (LEO80185 gel) | Phase 3 | Psoriasis of Scalp |
| LEO 43204 gel | Phase 3 | Actinic Keratosis |
| LEO 90100 Aerosol Foam | Phase 3 | Psoriasis Vulgaris |
| LEO 90100 foam | Phase 3 | Psoriasis Vulgaris |
| LEO43204 gel | Phase 3 | Actinic Keratosis |
| Tralokinumab | Phase 3 | Atopic Dermatitis |
| HL 10 | Phase 3 | Acute Lung Injury |
| Delgocitinib | Phase 3 | Chronic Hand Eczema |
| TMB-001 | Phase 3 | Ichthyosis |
| Tralokinumab + TCS | Phase 3 | Atopic Dermatitis |
| Calcipotriol plus hydrocortisone ointment vehicle | Phase 3 | Psoriasis Vulgaris |
| LEO 32731 | Phase 2 | Psoriasis Vulgaris |
| 2% TD1414 Cream | Phase 2 | Secondarily Infected Traumatic Lesions (SITL) |
| LEO 138559 | Phase 2 | Atopic Dermatitis |
| Azelaic Acid 15% Gel | Phase 2 | Seborrheic Dermatitis on the Face |
| Daivobet® ointment | Phase 2 | Psoriasis Vulgaris |
| Cromoglicate | Phase 2 | Psoriasis |
| Isotretinoin | Phase 2 | Congenital Ichthyosis |
| LEO 29102 | Phase 2 | Atopic Dermatitis |
| LEO 19123 Cream (calcipotriol plus LEO 80122) | Phase 2 | Psoriasis Vulgaris |
| Tarlatamab | Phase 1/2 | Glioma |
| AFXl-assisted ingenol mebutate delivery | Phase 1/2 | Carcinoma, Basal Cell |
| Tralokinumab administered as 1 × X mL with Device A | Phase 1 | Healthy |
| LEO 90105 | Phase 1 | Healthy |
| LEO 32731 modified release tablet | Phase 1 | Healthy |
| B LEO 35299 20 mg/g cream | Phase 1 | Psoriasis Vulgaris |
| ingenol mebutate 0.015% | Phase 1 | Actinic Keratoses |
| Ingenol once daily for two consecutive days | Phase 1 | Actinic Keratosis |
| LEO 39652 cream | Phase 1 | Atopic Dermatitis |
| Ingenol mebutate gel 0.05% | Phase 1 | Actinic Keratosis |
| Microarray patch A | Phase 1 | Psoriasis Vulgaris |
| topical formulation of tacrolimus | Phase 1 | |
| LEO 142397 | Phase 1 | |
| LEO 158968 | Phase 1 | |
| LEO 153339 | Phase 1 | |
| LEO32731 | Phase 1 | Psoriasis Vulgaris |
| Picato | Phase 1 | Molluscum Contagiosum |
| azelaic acid pre-foam formulation | Phase 1 | Healthy |
| Seocalcitol | Not Applicable | Liver Neoplasms |
| Thrombin Generation Assay (TGA) | Not Applicable | Cancer |
| Leukotriene B4 | Not Applicable | Skin Inflammation |
Latest
- PICATO: patent 9833428 expires 2026-12-18
- PICATO: patent 8372828 expires 2026-12-18
- PICATO: patent 8372827 expires 2026-12-18
- PICATO: patent 8377919 expires 2026-12-18
- PICATO: patent 9833429 expires 2026-12-18
Follow LEO Pharma on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.